目的 探討益肺膠囊聯(lián)合布地奈德氣霧劑霧化吸入治療慢性阻塞性肺疾病急性加重期臨床療效。方法 選取2016年3月—2017年2月太倉市中醫(yī)醫(yī)院收治的慢性阻塞性肺疾病急性加重期患者92例為研究對象，按照隨機數(shù)字表法將所有患者分為對照組和治療組，每組各46例。對照組霧化吸入布地奈德氣霧劑，1 000 μg/次，1次/d。治療組在對照組基礎(chǔ)上口服益肺膠囊，1.2 g/次，3次/d。兩組患者均連續(xù)治療2個月。觀察兩組的臨床療效，比較兩組的免疫功能和肺功能。結(jié)果 治療后，對照組和治療組的總有效率分別為73.91%、91.30%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，治療組自然殺傷（NK）細胞、CD³⁺、CD⁴⁺、CD⁴⁺/CD⁸⁺水平均明顯升高，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些觀察指標明顯高于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組一秒用力呼氣容積（FEV1）、FEV1/用力肺活量（FVC）、最大呼氣流速（PEF）、第1秒用力呼氣容積占預(yù)計值百分比（FEV1% pred）均明顯升高，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些觀察指標明顯高于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 益肺膠囊聯(lián)合布地奈德氣霧劑霧化治療慢性阻塞性肺疾病急性加重期具有較好的臨床療效，能改善肺功能，調(diào)節(jié)免疫功能，具有一定的臨床推廣應(yīng)用價值。

objective To investigate the effect of Yifei Capsules combined with aerosolized Budesonide Aerosol inhalation in treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods Patients (92 cases) with acute exacerbation of chronic obstructive pulmonary disease in Taicang Hospital of Traditional Chinese Medicine from March 2016 to February 2017 were divided into control and treatment groups according to the random number table method, and each group had 46 cases. Patients in the control group were atomization inhalation administered with Budesonide Aerosol, 1 000 μg/time, once daily. Patients in the treatment group were po administered with Yifei Capsules on the basis of the control group, 1.2 g/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacies were evaluated, and immune function and lung function in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 73.91% and 91.30%, respectively, and there was difference between two groups (P < 0.05). After treatment, the level of NK, CD³⁺, CD⁴⁺, and CD⁴⁺/CD⁸⁺ in the treatment group were significantly increased (P < 0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). After treatment, FEV1, FEV1/FVC, PEF, and FEV1% pred in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Yifei Capsules combined with aerosolized Budesonide Aerosol inhalation has clinical curative effect in inhalation treatment of acute exacerbation of chronic obstructive pulmonary disease, can improve lung function, and regulate immune function, which has a certain clinical application value.